Page 23 - The DHEA Debate - Life Extensions Magazine

79. Orner GA, Mathews C, Hendricks JD, Carpenter HM, Bailey GS, Williams DE.
Dehydroepiandrosterone is a complete hepatocarcinogen and potent tumor promoter in the
absence of peroxisome proliferation in rainbow trout. Carcinogenesis. 1995 Dec;16(12):2893-8.

80. Jozuka H, Jozuka E, Suzuki M, Takeuchi S, Takatsu Y. Psycho-neuro-immunological
treatment of hepatocellular carcinoma with major depression. Curr Med Res Opin.
2003;19(1):59-63.
81. Kavanaugh C, Green JE. The use of genetically altered mice for breast cancer prevention
studies. J Nutr. 2003 Jul; 133(7 Suppl):2404S-2409S.
82. Regelson W, Loria R, Kalimi M. Dehydroepiandrosterone (DHEA) I: immunologic action.
Ann NY Acad Sci. 1994 May 31;719:553-563.

83. Green JE, Shibata MA, Shibata E, et al. 2-Difluoromethylornithine and dehy-
droepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor
initiation in C3(1)/SV40 T/t-antigen transgenic mice. Cancer Res. 2001 Oct 15;61(20):7449-55.
84. Perkins SN, Hursting SD, Kim K, Poetschke K, Heather L, Richie ER. Mechanisms
underlying the anti-lymphoma activity of dehydroepiandrosterone: studies in murine thymocytes
and murine T-cell hybridoma cells. Cancer Epidemiology Biomarkers & Prevention. 2002;
11(10):1233s.

85. Perkins SN, Hursting SD, Haines DC, James SJ, Miller BJ, Phang JM. Chemoprevention of
spontaneous tumorigenesis in nullizygous p53-deficient mice by dehydroepiandrosterone and
its analog 16alpha-fluoro-5-androsten-17-one. Carcinogenesis. 1997 May;18(5):989-94.
86. Perkins SN. Dietary modulation of cell cycle regulators. NCI grant. Federal research in
progress (FRP). NDN 049- 0652-1518-9.
87. Hsu HC. Dehydroepiandrosterone (DHEA) sulfotransferase gene expression in human
hepatocellular carcinoma: an age-dependent prognostic factor. Proc Am Assoc Cancer Res.
1995;36:208.

88. Osawa E, Hakajima A, Yoshida S, et al. Chemoprevention of precursors to colon cancer by
dehydroepiandrosterone (DHEA). Life Sci. 2002 Apr 19; 70(22):2623-30.
89. Yang S, FuZ, Wang F, Cao Y, Han R. Antimutagenic activity of dehydroepiandrosterone.
Zhonghua Zhong Liu Za Zhi. 2002 Mar; 24(2):137-40.
90. Bulbrook RD, Hayward JL, Spicer CC. Relation between urinary androgen and corticoid
excretion and subsequent breast cancer. Lancet. 1971 Aug 21; 2(7721):395- 98.
91. Eaton NE, Reeves GK, Appleby PN, Key TJ. Endogenous sex hormones and prostate
cancer: a quantitative review of prospective studies. Br J Cancer. 1999 Jun;80(7):930-4.
92. Vatten LJ, Ursin G, Ross RK, et al. Androgens in serum and the risk of prostate cancer: a
nested case-control study from the Janus serum bank in Norway. Cancer Epidemiol Biomarkers
Prev.1997 Nov;6(11):967-9.
93. Stahl F, Schnorr D, Pilz C, Dorner G. Dehydroepiandrosterone (DHEA) levels in patients
with prostatic cancer, heart disease, and under surgery stress. Exp Clin Endocrinol. 1992;
99(2):68-70.

94. Schatzl G, Madersbacher S, Thurridl T, et al. High-grade prostate cancer is associated with
low serum testosterone levels. Prostate. 2001 Apr;47(1):52-8.